Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.23.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2022

378,897

$

26.15

Granted

1,103,698

2.33

Forfeited

(45,100)

6.89

Vested

(106,209)

24.78

Non-vested at September 30, 2023

1,331,286

$

7.16

Summary of restricted stock units activity

    

    

Weighted Average

Number of

Grant Date Fair

Shares

Value

Non-vested at December 31, 2022

 

85,000

$

10.50

Granted

 

577,384

 

2.25

Vested

(42,500)

10.50

Non-vested at September 30, 2023

 

619,884

$

2.82

Summary of stock option award activity

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2022

27,000

$

31.35

6.44

Granted

100,000

2.81

Outstanding as of September 30, 2023

127,000

$

8.88

8.85

Vested and exercisable as of September 30, 2023

19,500

$

24.68

6.29

Summary of stock options assumptions used

For the Nine Months Ended September 30,

 

2023

    

2022

 

Risk-free interest rate

    

3.73

%  

1.30

%

Expected dividend yield

 

 

Expected term in years

 

10.0

 

10.0

Expected volatility

 

83.48

%  

100.65

%

Summary of warrant activities

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2022

4,357,597

$

3.37

3.26

Granted

22,483,346

2.89

Exercised

(3,448,147)

Outstanding as of September 30, 2023

23,392,796

$

3.40

2.88

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2023 and 2022 ($ in thousands):

For the three months ended September 30, 

For the nine months ended September 30, 

    

2023

    

2022

    

2023

    

2022

Research and development

$

304

$

276

$

881

$

752

General and administrative

 

385

505

1,344

1,533

Total stock-based compensation expense

$

689

$

781

$

2,225

$

2,285